Key Points
- CEO Chad Robins sold 124,998 shares on Jan. 5 at an average of $15.59 for about $1.95 million, leaving him with 2,584,243 shares — a 4.61% reduction in his stake.
- Quarterly results showed revenue of $93.97M (vs. $58.76M expected), a 102.4% year‑over‑year increase, but the company still reported negative EPS of ($0.15) and negative margins/ROE.
- Analyst sentiment is mostly positive (nine Buys, one Hold, one Sell) with a consensus target of $17.11; the stock traded around $16.73 (up ~3.8%) and the market cap is about $2.55 billion.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of Adaptive Biotechnologies stock in a transaction on Monday, January 5th. The shares were sold at an average price of $15.59, for a total transaction of $1,948,718.82. Following the completion of the sale, the chief executive officer owned 2,584,243 shares of the company's stock, valued at $40,288,348.37. This represents a 4.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Adaptive Biotechnologies Stock Up 3.8%
Shares of NASDAQ ADPT opened at $16.73 on Thursday. The firm has a market cap of $2.55 billion, a PE ratio of -30.98 and a beta of 2.18. The company's fifty day simple moving average is $16.50 and its 200 day simple moving average is $14.24. Adaptive Biotechnologies Corporation has a 12-month low of $5.97 and a 12-month high of $20.76.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. The firm had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The business's quarterly revenue was up 102.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.22) earnings per share. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages have commented on ADPT. Cowen restated a "buy" rating on shares of Adaptive Biotechnologies in a research note on Wednesday. Piper Sandler boosted their price objective on Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an "overweight" rating in a report on Wednesday, October 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. BTIG Research lifted their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, November 6th. Finally, Guggenheim initiated coverage on Adaptive Biotechnologies in a research report on Tuesday, September 30th. They issued a "buy" rating and a $20.00 price target for the company. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $17.11.
Check Out Our Latest Stock Report on Adaptive Biotechnologies
Hedge Funds Weigh In On Adaptive Biotechnologies
Several institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of Adaptive Biotechnologies by 3.1% during the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company's stock valued at $349,000 after buying an additional 700 shares during the last quarter. Bouvel Investment Partners LLC raised its stake in Adaptive Biotechnologies by 2.2% in the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company's stock valued at $641,000 after acquiring an additional 904 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Adaptive Biotechnologies by 3.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company's stock valued at $355,000 after purchasing an additional 910 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Adaptive Biotechnologies by 1.0% during the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company's stock valued at $1,145,000 after purchasing an additional 933 shares during the last quarter. Finally, Captrust Financial Advisors boosted its position in Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company's stock worth $184,000 after purchasing an additional 1,119 shares during the period. 99.17% of the stock is owned by institutional investors.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
